BR112016030758B8 - Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal - Google Patents

Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal

Info

Publication number
BR112016030758B8
BR112016030758B8 BR112016030758A BR112016030758A BR112016030758B8 BR 112016030758 B8 BR112016030758 B8 BR 112016030758B8 BR 112016030758 A BR112016030758 A BR 112016030758A BR 112016030758 A BR112016030758 A BR 112016030758A BR 112016030758 B8 BR112016030758 B8 BR 112016030758B8
Authority
BR
Brazil
Prior art keywords
strome
multipotent
adipose tissue
cells derived
mesenchymal
Prior art date
Application number
BR112016030758A
Other languages
English (en)
Other versions
BR112016030758B1 (pt
BR112016030758A2 (pt
Inventor
Dalemans Wilfried
Lombardo Eleuterio
Dekker Robert
Original Assignee
Tigenix S A U
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tigenix S A U, Takeda Pharmaceuticals Co filed Critical Tigenix S A U
Publication of BR112016030758A2 publication Critical patent/BR112016030758A2/pt
Publication of BR112016030758B1 publication Critical patent/BR112016030758B1/pt
Publication of BR112016030758B8 publication Critical patent/BR112016030758B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor

Abstract

COMPOSIÇÃO, USO DE CÉLULAS ESTROMAIS MESENQUIMAIS NA MANUFATURA DE UM MEDICAMENTO, E, MÉTODO DE TRATAMENTO DE SEPSE EM UM INDIVÍDUO. A invenção se refere ao uso de células estromais mesenquimais (MSCs) para o tratamento de sepse em um indivíduo. A invenção prove composições, usos e métodos para o tratamento de sepse.
BR112016030758A 2014-06-30 2015-06-30 Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal BR112016030758B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14175095 2014-06-30
EP14175095.0 2014-06-30
PCT/IB2015/054923 WO2016001846A1 (en) 2014-06-30 2015-06-30 Mesenchymal stromal cells for treating sepsis

Publications (3)

Publication Number Publication Date
BR112016030758A2 BR112016030758A2 (pt) 2017-08-22
BR112016030758B1 BR112016030758B1 (pt) 2021-10-13
BR112016030758B8 true BR112016030758B8 (pt) 2022-10-25

Family

ID=51033023

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016030758A BR112016030758B8 (pt) 2014-06-30 2015-06-30 Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal

Country Status (14)

Country Link
US (2) US20170151284A1 (pt)
EP (1) EP3160481B1 (pt)
JP (1) JP6722599B2 (pt)
KR (1) KR102213527B1 (pt)
CN (1) CN106573017B (pt)
AU (1) AU2015283662B2 (pt)
BR (1) BR112016030758B8 (pt)
CA (1) CA2953884C (pt)
IL (1) IL249814B (pt)
MX (1) MX2017000142A (pt)
NZ (1) NZ727950A (pt)
RU (1) RU2715866C2 (pt)
SG (1) SG11201610844PA (pt)
WO (1) WO2016001846A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6714932B2 (ja) * 2015-12-01 2020-07-01 株式会社ＡｄｉｐｏＳｅｅｄｓ 脊椎動物の脂肪組織由来間葉系細胞株の製造方法
WO2017156235A1 (en) * 2016-03-09 2017-09-14 Emory University Methods of preserving mesenchymal stem cells
GB201604304D0 (en) * 2016-03-14 2016-04-27 Tigenix S A U Adipose tissue-derived stromal stem cells for use in treating refractory complex perianal fistulas in crohn's disease
EP4091618A1 (fr) 2017-02-28 2022-11-23 Université de Lorraine Cellules souches mesenchymateuses issues de la gelée de wharton pour le traitement du sepsis
WO2019084010A1 (en) 2017-10-26 2019-05-02 Emory University MCL-1 INHIBITORS, COMPOSITIONS AND USES IN CANCER CARE
CA3100471A1 (en) * 2018-06-05 2019-12-12 Medipost Co., Ltd. Pharmaceutical composition comprising mesenchymal stem cells as effective ingredient for prevention or treatment of inflammatory disease
ES2962812T3 (es) * 2018-10-29 2024-03-21 Ottawa Hospital Res Inst Células madre mesenquimatosas modificadas genéticamente que sobreexpresan AOAH y sus usos
US20230086254A1 (en) * 2020-01-30 2023-03-23 Jcr Pharmaceuticals Co., Ltd. Medicinal composition comprising dental pulp-derived cells
CN117835994A (zh) * 2021-05-13 2024-04-05 普干基因美国有限公司 用于治疗肝病的方法和组合物
CN113398150A (zh) * 2021-06-18 2021-09-17 卡替(上海)生物技术有限公司 牙髓间充质干细胞在脓毒症治疗中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69317439T2 (de) 1992-12-02 1998-07-02 Shell Int Research Azoxycyanbenzol-Derivate
WO1995002698A1 (en) 1993-07-12 1995-01-26 Life Technologies, Inc. Composition and methods for transfecting eukaryotic cells
JP4335310B2 (ja) 1995-06-07 2009-09-30 ザ ユニバーシティ オブ ブリティッシュ コロンビア 疎水性脂質−核酸複合中間体を通して調製される脂質−核酸粒子、及び遺伝子移送のための使用
US6051429A (en) 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US5744335A (en) 1995-09-19 1998-04-28 Mirus Corporation Process of transfecting a cell with a polynucleotide mixed with an amphipathic compound and a DNA-binding protein
US5705308A (en) 1996-09-30 1998-01-06 Eastman Kodak Company Infrared-sensitive, negative-working diazonaphthoquinone imaging composition and element
US6777231B1 (en) 1999-03-10 2004-08-17 The Regents Of The University Of California Adipose-derived stem cells and lattices
EP2298861B1 (en) * 2004-03-22 2017-09-13 Mesoblast International Sàrl Mesenchymal stem cells and uses therefor
JP5925408B2 (ja) 2005-09-23 2016-05-25 タイジェニックス、ソシエダッド、アノニマ、ウニペルソナルＴｉｇｅｎｉｘ Ｓ．Ａ．Ｕ． 免疫調節活性を有する細胞集団、単離方法および使用
GB0814249D0 (en) * 2008-08-04 2008-09-10 Cellerix Sa Uses of mesenchymal stem cells
ES2629502T3 (es) * 2011-03-11 2017-08-10 Children's Medical Center Corporation Métodos y composiciones relacionados con exosomas de células madre mesenquimales
JP2014016782A (ja) * 2012-07-09 2014-01-30 Toshiba Corp 情報処理装置およびプログラム
US20140134140A1 (en) * 2012-11-09 2014-05-15 Case Western Reserve University Mesenchymal stem cell compositions for the treatment of microbial infections

Also Published As

Publication number Publication date
IL249814B (en) 2020-02-27
AU2015283662A1 (en) 2017-01-19
US20200376038A1 (en) 2020-12-03
US20170151284A1 (en) 2017-06-01
KR20170021343A (ko) 2017-02-27
CN106573017B (zh) 2021-06-11
CA2953884A1 (en) 2016-01-07
RU2016151738A3 (pt) 2019-01-30
CA2953884C (en) 2022-12-06
WO2016001846A1 (en) 2016-01-07
JP6722599B2 (ja) 2020-07-15
RU2016151738A (ru) 2018-07-30
EP3160481A1 (en) 2017-05-03
CN106573017A (zh) 2017-04-19
SG11201610844PA (en) 2017-01-27
EP3160481B1 (en) 2020-09-09
JP2017520583A (ja) 2017-07-27
BR112016030758B1 (pt) 2021-10-13
AU2015283662B2 (en) 2020-09-24
KR102213527B1 (ko) 2021-02-09
MX2017000142A (es) 2017-07-28
IL249814A0 (en) 2017-03-30
RU2715866C2 (ru) 2020-03-03
BR112016030758A2 (pt) 2017-08-22
NZ727950A (en) 2022-07-01

Similar Documents

Publication Publication Date Title
BR112016030758B8 (pt) Uso de células estromais multipotentes derivadas de tecido adiposo mesenquimal
CL2016002751A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
BR112017013143A2 (pt) geração de ácido peroxifórmico através de formiato de álcool poli-hídrico
CO2017005371A2 (es) Sistema para la preparación de plasma rico en plaquetas, concentrado de médula ósea, una composición y su método de obtención
BR112016025132A2 (pt) compostos polifluorados agindo como inibidores de tirosina quinase de bruton
DK3692857T3 (da) Indretning til levering af hudplejesammensætning
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
EA201692529A1 (ru) Способы и композиции для лечения расстройств с использованием фоллистатиновых полипептидов
EA201790273A1 (ru) Флагеллиновые композиции и их применение
UY33917A (es) ?composiciones para recubrimiento que comprenden submicropartículas que comprenden carbonato de calcio, proceso para prepararlas, y uso de las submicropartículas?.
CL2015002897A1 (es) Inhibidores de bace1
DOP2017000146A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2
MX362471B (es) Composiciones para el cuidado bucal que tienen estabilidad mejorada.
BR112017006085A2 (pt) compostos 1-alquil-6-oxo-1,6-di-hidropiridin-3-ila e uso como moduladores sgrm
DK3189844T3 (da) Pluripotent stamcelle til behandling af diabetisk hudsår
DOP2016000073A (es) Composiciones y métodos para inhibir la expresión del gen alas1
BR112017009289A2 (pt) métodos de administrar composições de amantadina
EP3342858A4 (en) ROR1-POSITIVE MESENCHYMAL STEM CELLS AND PREPARATION METHOD THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PREPARATION METHOD THEREOF, AND METHOD FOR PREVENTING OR TREATING DISEASES USING SAID ROR1 POSITIVE MESENCHYMAL STEM CELLS
NZ703345A (en) Compositions and methods for reducing frequency and/or severity of headache
BR112018008931A2 (pt) ?compostos para tratamento de distúrbios hipoproliferativos?
MX2016009655A (es) Metodos novedosos para el tratamiento del cancer.
HK1254588A1 (zh) 間充質幹細胞用於治療骨關節炎的用途
EA201691493A1 (ru) Замещенные n-арилпиридиноны
SG10202010615QA (en) Method for promoting and improving properties of adipose tissue, tissue and cells obtained by said method
GT201500056S (es) Aparato para peinar el cabello

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 30/06/2015, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP)